Patents Issued in January 21, 2020
  • Patent number: 10537566
    Abstract: The present invention relates to combinations and pharmaceutical compositions comprising siponimod and laquinimod, and the use of said combinations and/or compositions for the treatment of multiple sclerosis, particularly secondary progressive multiple sclerosis.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: January 21, 2020
    Assignee: Novartis AG
    Inventor: Paul Alfred Smith
  • Patent number: 10537567
    Abstract: Disclosed are therapeutic compositions including BA-1076 and/or BA-2057, methods of their use in the treatment of ophthalmological disorders. The therapeutic compositions may further include an IOP-lowering prostaglandin. The methods may further include administration of an IOP-lowering prostaglandin.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: January 21, 2020
    Assignee: BioAxone BioSciences, Inc.
    Inventors: Joerg Ruschel, Matthew D. Abbinanti, Kenneth M. Rosen, Lisa McKerracher
  • Patent number: 10537568
    Abstract: The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient. The combination can be useful during and following radiation exposure to ameliorate the inflammatory response.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: January 21, 2020
    Assignee: IRR, Inc.
    Inventor: Bruce Chandler May
  • Patent number: 10537569
    Abstract: The present invention relates to sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine and pharmaceutically acceptable solvates thereof, preparation thereof, pharmaceutical compositions containing them and use of the same in the treatment and/or prevention of neurodegenerative diseases.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: January 21, 2020
    Assignees: ALZPROTECT, Universite de Lille 2 Droit et Saute, Inserm (Institut National De La Saute et de la Recherche Medicale
    Inventors: Stéphane Burlet, Cécilia Estrella, Mathieu Barrier, Patricia Melnyk, Nicolas Sergeant, Luc Buee, Philippe Verwaerde
  • Patent number: 10537570
    Abstract: The invention relates to pimobendan for use in a method of reducing the heart size and/or delaying the onset of clinical symptoms in a patient suffering from asymptomatic (occult, preclinical) heart failure, preferably congestive heart failure, due to mitral valve disease (MVD), and/or delaying the onset of heart failure, preferably congestive heart failure, in a patient suffering from asymptomatic (occult, preclinical) heart failure, preferably congestive heart failure, due to mitral valve disease (MVD), wherein the patient is preferably a mammal, more preferably a human, a dog, a cat or a horse, and most preferably a dog.
    Type: Grant
    Filed: April 3, 2017
    Date of Patent: January 21, 2020
    Inventors: Christoph Schummer, Olaf Joens
  • Patent number: 10537571
    Abstract: Provided herein are compounds of Formula I useful as FGFR4 inhibitors, as well as methods of use of the same.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: January 21, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Dominic Reynolds, Ming-Hong Hao, John Wang, Sudeep Prajapati, Takashi Satoh, Anand Selvaraj
  • Patent number: 10537572
    Abstract: The present disclosure relates to the use of GnRH receptor antagonists used in the treatment of endometriosis or uterine fibroids. In particular, the present disclosure describes a method of treating endometriosis or uterine fibroids, where the method involves the administration of elagolix, and where the method may further involve the co-administration of rifampin or ketoconazole.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: January 21, 2020
    Assignee: AbbVie Inc.
    Inventors: Sandra L. Goss, Cheri E. Klein, Juki Wing-Keung Ng, Ahmed Salem
  • Patent number: 10537573
    Abstract: The present invention relates to combinations comprising a positive allosteric modulator (“PAM”) of metabotropic glutamatergic receptor subtype 2 (“mGluR2”) or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric agonist of metabotropic glutamatergic receptor subtype 2 compound or a pharmaceutically acceptable salt or a solvate thereof, and a synaptic vesicle protein 2A (“SV2A”) ligand.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: January 21, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Brian D. Klein, Hilde Lavreysen, Stefan Maria Christiaan Pype, Roy E. Twyman, Nancy Eulalie Sylvain Van Osselaer, H. Steven White, Marc André Ceusters, José Maria Cid-Núñez, Andrés Avelino Trabanco-Suárez, Roger Francis Bone
  • Patent number: 10537574
    Abstract: This disclosure relates to the use of kinase inhibitor to treat or prevent infectious diseases such as tuberculosis. In certain embodiments, this disclosure relates to treating or preventing an infectious disease comprising administering an effective amount of a kinase inhibitor or other compound disclosed herein to a subject in need thereof. In certain embodiments, the disclosure relates to methods of treating or preventing tuberculosis comprising administering a kinase inhibitor to a subject in need thereof. In certain embodiments, the subject is diagnosed with Mycobacterium tuberculosis (Mtb) that is resistant to multiple antibiotic agents.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: January 21, 2020
    Assignee: Emory University
    Inventor: Daniel Kalman
  • Patent number: 10537575
    Abstract: The present disclosure concerns the use of a phosphodiesterase inhibitor, such as, for example, sildenafil, to repair a brain and/or a retinal injury in a newborn. The phosphodiesterase inhibitor can be used in a premature or a term baby that has been exposed to hyperoxia or hypoxia which caused a brain and/or a retinal injury.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: January 21, 2020
    Inventor: Pia Wintermark
  • Patent number: 10537576
    Abstract: Methods of treating breast cancer are provided where a quantitative Her2 assay is used to identify whether a breast tumor will be responsive to treatment with anti-Her2 therapeutic agents such as lapatinib and trastuzumab, followed by selection of a suitable treatment regimen and administration of the regimen. A specific Her2 fragment peptide is precisely quantitated by SRM-mass spectrometry directly in breast tumor cells collected from breast tumor tissue that was obtained from a cancer patient and compared to a reference level in order to determine if the breast cancer patient will positively respond to treatment with a therapeutic agent that specifically targets the Her2 protein.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: January 21, 2020
    Assignee: Expression Pathology, Inc.
    Inventors: Adele Blackler, Todd Hembrough, Fabiola Cecchi, Paolo Nuciforo
  • Patent number: 10537577
    Abstract: The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: January 21, 2020
    Assignees: Emory University, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Scott D. Boden, Sreedhara Sangadala
  • Patent number: 10537578
    Abstract: This disclosure pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiaziniumcompounds”) including Methythioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt-formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). Also disclosed resulting (high purity) compounds, compositions comprising them (e.g.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: January 21, 2020
    Inventors: John Mervyn David Storey, James Peter Sinclair, Colin Marshall, Han Wan Tan, Claude Michel Wischik
  • Patent number: 10537579
    Abstract: To provide a novel method for suppressing rejection after corneal transplantation. The method for suppressing rejection after corneal transplantation includes administering an effective amount of a Rho kinase inhibitor to a patient who needs it.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: January 21, 2020
    Assignees: JUNTENDO EDUCATIONAL FOUNDATION, KOWA COMPANY, LTD.
    Inventors: Takenori Inomata, Toshinari Funaki
  • Patent number: 10537580
    Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: January 21, 2020
    Assignee: NOVIRA THERAPEUTICS, INC.
    Inventors: George D. Hartman, Scott Kuduk
  • Patent number: 10537581
    Abstract: According to various embodiments of this disclosure, pharmaceutical compositions comprising solubilized estradiol are provided. In various embodiments, such compositions are encapsulated in soft capsules which may be vaginally inserted for the treatment of vulvovaginal atrophy.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: January 21, 2020
    Assignee: TherapeuticsMD, Inc.
    Inventors: Brian A. Bernick, Thorsteinn Thorsteinsson, Peter H. R. Persicaner, Janice Louise Cacace, Frederick D. Sancilio, Neda Irani, Julia Amadio
  • Patent number: 10537582
    Abstract: A method for contraception includes administering to a female daily, in a fourphasic dosing regimen during a time period of 24 successive days, an oral combination drug formulation of norethindrone acetate and ethinyl estradiol (EE), wherein doses in the second, third and fourth phases of the regimen increase by a predefined dose increment as compared to the corresponding doses administered during the previous phase, wherein the norethindrone acetate dose in the first phase is 1000 mcg, in the second phase is 1125 mcg, in the third phase is 1250 mcg, and in the fourth phase is 1375 mcg, wherein the EE dose in the first phase is 20 mcg, in the second phase is 22.5 mcg, in the third phase is 25 mcg, and in the fourth phase is 27.5 mcg, and wherein the fourphasic dosing regimen is followed by 4 days without norethindrone acetate and EE administration.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: January 21, 2020
    Assignee: ARSTAT, INC.
    Inventor: Arkady Rubin
  • Patent number: 10537583
    Abstract: An oral formulation, and preparation method and use thereof; the oral formulation comprises 1-50 parts by weight of an A-nor-5a-androstane compound, 20-95 parts by weight of a filling agent, 0-20 parts by weight of a disintegrant, 0.1-30 parts by weight of a binder, 0.1-5 parts by weight of a lubricant and 0.1-5 parts by weight of a glidant. The oral formulation has a high stability and a good dissolution performance.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: January 21, 2020
    Inventor: Yajun Chen
  • Patent number: 10537584
    Abstract: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: January 21, 2020
    Assignee: FERRING B.V.
    Inventors: Salah U. Ahmed, Jiaxiang Tsao, Anu Mahashabde, Diane D. Harrison
  • Patent number: 10537585
    Abstract: A pharmaceutical composition useful for the treatment of multiple myeloma in combination with an anti-cancer drug is provided. The pharmaceutical composition includes high-dose dexamethasone or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: January 21, 2020
    Assignee: DEXCEL PHARMA TECHNOLOGIES LTD.
    Inventors: Caterina Kreyenborg, Elisabeth Meimberg, Corinna Tissen, Karl-Heinz Bannefeld, Tomer Gold
  • Patent number: 10537586
    Abstract: This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: January 21, 2020
    Assignee: POP TEST ONCOLOGY LLC
    Inventors: Randice Lisa Altschul, Neil David Theise, Myron Rapkin, Rebecca O'Brien
  • Patent number: 10537587
    Abstract: Described herein are combination therapies for cancer (such as lymphoid malignancies) and immune diseases (such as autoimmune diseases and inflammatory diseases). The therapies comprise the combined use of inhibitors of BTK, mTOR kinase, and Bcl-2 or their signaling pathways, and immunomodulatory drugs. Also described are pharmaceutical compositions and kits comprising these inhibitors.
    Type: Grant
    Filed: September 6, 2018
    Date of Patent: January 21, 2020
    Assignee: ZHEJIANG DTRM BIOPHARMA CO. LTD.
    Inventor: Wei He
  • Patent number: 10537588
    Abstract: A phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: January 21, 2020
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann
  • Patent number: 10537589
    Abstract: The present invention is directed to methods for inhibition of HIV reverse transcriptase, treatment of infection by HIV, prophylaxis of infection by HIV, and the treatment, prophylaxis and/or delay in the onset or progression of AIDS or ARC by administering a compound of structural Formula I or a pharmaceutically acceptable salt or co-crystal thereof, wherein X is —F or —Cl, less frequently than once daily.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: January 21, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Daria Hazuda, Michael D. Miller, Jay A. Grobler, Deborah Anne Nicoll-Griffith
  • Patent number: 10537590
    Abstract: The present invention relates to compounds of general formula I, wherein the groups R1, R2 and R3 are defined as in claim 1, which have valuable pharmacological properties, particularly are modulators of STING.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: January 21, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thorsten Oost, Sebastian Carotta, Martin Fleck
  • Patent number: 10537591
    Abstract: The invention solves the problem of providing new therapies that are effective in the treatment of muscular dystrophies through the use of compositions comprising a compound capable of reducing the expression of miRNA-106b in muscle satellite stem cells of a human or animal subject with respect to the expression observed in the absence of the compound in said cells.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: January 21, 2020
    Assignee: UNIVERSIDAD DE JAEN
    Inventors: Amelia Eva Aranega Jimenez, Diego Franco Jaime, Francisco Hernandez Torres, Estefania Lozano Velasco, Daniel Vallejo Pulido
  • Patent number: 10537592
    Abstract: The disclosure relates to decarboxylated cannabis resins and methods of making the decarboxylated cannabis resins by extraction and decarboxylation of cannabinoids from Cannabis species using microwaves and solvents. The disclosure also relates to use of the decarboxylated cannabis resins for making pharmaceutical products comprising same.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: January 21, 2020
    Assignee: CannScience Innovations Inc.
    Inventors: Lakshmi Premakanth Kotra, Melissa Maureen Lewis, Ewa Wasilewski, Har Grover
  • Patent number: 10537593
    Abstract: Provided are a method, target and application for NO accumulation to decrease invasiveness of Pseudomonas aeruginosa; achieving NO accumulation by means of external NO donors or disruption of internal NO metabolism in an environment where Pseudomonas aeruginosa is growing or being cultured, in order to decrease production by Pseudomonas aeruginosa of the invasion factor pyocyanin. Utilizing even micro-quantities of NO can significantly inhibit Pseudomonas aeruginosa PCN (PCN synthesis down 82% with 60 ?M SNP treatment); by inhibiting NO reductase, an enzyme related to NO metabolism, PCN synthesis can be significantly inhibited (the PAO1-?nor strain has 84% PCN reduction). Using NO donors or inhibiting enzymes involved in Pseudomonas aeruginosa NO metabolism as a means of combating bacterial infectious disease does not affect the body's normal microflora like traditional antibiotics.
    Type: Grant
    Filed: October 22, 2016
    Date of Patent: January 21, 2020
    Inventors: Yi Wan, Chang Chen, Lei Gao, Yuying Zhang, Xinhua Qiao, Yan Wang
  • Patent number: 10537594
    Abstract: The present disclosure relates to, inter alia, compositions and kits comprising an asialoglycoprotein covalently attached to a polycation, and functional mammalian mitochondria that are at least partially purified and are electrostatically bound to the AsG-polycation molecule; as well as methods of their preparation and use.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: January 21, 2020
    Assignee: University of Connecticut
    Inventors: George Y Wu, Catherine H Wu, Nidhi Gupta
  • Patent number: 10537595
    Abstract: The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: January 21, 2020
    Assignee: Iovance Biotherapeutics, Inc.
    Inventors: Seth Wardell, James Bender, Michael T. Lotze
  • Patent number: 10537596
    Abstract: The embodiments disclosed herein generally relate to systems, devices and methods for the fractionation, isolation, extraction and processing of the adipose supernatant layer of a bone marrow aspirate. In particular, the various embodiments relate to systems devices and methods of obtaining, utilizing and processing the adipose supernatant layer of a bone marrow aspirate as a source of mesenchymal stem cells.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: January 21, 2020
    Assignee: Regenexx LLC
    Inventors: Christopher Centeno, Ryan Dregalla, Nicolette Lyons, Patrick Reischling
  • Patent number: 10537597
    Abstract: The invention relates to use of Akkermansia muciniphila, a mucin-degrading bacterial species found in the human gut, for treating undesirable inflammatory activity not caused by any metabolic disorder and/or obesity, especially for example undesirable airway inflammatory activity as seen with asthma.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: January 21, 2020
    Assignee: Schweizerisches Forschungsinstitut Fur Hochgebrigsklima Und Medizin In Davos
    Inventors: Liam O'Mahony, Cezmi A. Akdis, David Michalovich, Edith M. Hessel, James R. Brown, David N. Mayhew, Sorif Uddin
  • Patent number: 10537598
    Abstract: The present invention comprises a method for selecting lactic acid bacterial strains effective for preventing bone loss in humans and strains that have been selected according to the presented method. The selection method is based on the strains capability of reestablishing an altered microbial community to normal and/or harboring at least one of four specific SNPs.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: January 21, 2020
    Assignees: BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY, BIOGAIA AB
    Inventors: Eamonn Connolly, Robert Allen Britton, Laura Rae McCabe
  • Patent number: 10537599
    Abstract: A method for selecting cancer patient for treatment with Seneca Valley Virus (SVV) by determining expression of ANTXR1 in a cancerous tissue in a cancer patient; and designating the cancer patient as a candidate for treatment with SVV if normal levels or elevated levels of ANTXR1 expression is detected in the cancerous tissue. Also a method for treating a cancer patient with SVV is disclosed.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: January 21, 2020
    Assignee: Memorial Sloan-Kettering Cancer Center
    Inventors: Linde Miles, John Poirier, Charles Rudin
  • Patent number: 10537600
    Abstract: The present invention relates to a traditional Chinese medicine composition for regulating immunity and preparation method thereof, characterized in that the composition comprises raw materials such as Radix Panacis Quinquefolii, Ganoderma, fermented Cordyceps sinensis powder, Flos Rosae Rugosae, and Rhizoma Anemarrhenae and is prepared into various conventional pharmaceutical formulations through processes such as pulverization, water decoction and alcohol extraction. The traditional Chinese medicine composition is effective in preventing and treating allergic diseases, hepatitis B and AIDS, elevating leukocytes, preventing and treating radiation injury, reducing toxic and side effects resulting from radiotherapy and chemotherapy, improving the male sexual function, enhancing immunity of the human body and alleviating physical fatigue.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: January 21, 2020
    Assignee: JIANGZHONG PHARMACEUTICALS CO., LTD.
    Inventors: Hongguang Zhong, Minzhi Yi, Jianzhong Lu
  • Patent number: 10537601
    Abstract: The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from Baphicacanthus cusia. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from Baphicacanthus cusia.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: January 21, 2020
    Assignee: MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Jing-Rong Wang, Zhi-Hong Jiang, Qi-Tong Feng, Guo-Yuan Zhu, Wei-Na Gao, Zifeng Yang, Nanshan Zhong
  • Patent number: 10537602
    Abstract: A fish feed includes carvacrol and/or salvia extract (provided that where the fish feed comprises carvacrol and not salvia extract the lipid content of the fish feed is at least 15 wt %). The salvia extract may be selected from extract of Salvia officinalis and extract of Salvia lavandulifolia. The carvacrol may be synthetic or may be extracted from Origanum vulgare.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: January 21, 2020
    Assignee: NUTRECO IP ASSETS B.V.
    Inventors: Wolfgang Koppe, Alex Obach, Ramon Fontanillas
  • Patent number: 10537603
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating angioedema, containing as an active ingredient a peony root extract or an extract of a mixture of peony root and licorice. In particular, the extract of a mixture of peony root and licorice according to the present invention inhibits the excessive generation of advanced glycation end products, which may cause macular degeneration, inhibits blood-retinal barrier breakdown causing retinal edema in various animal models, protects or treats a subretinal region causing dry macular degeneration, inhibits angiogenesis causing wet macular degeneration, and thus can be usefully used as an active ingredient for the composition for preventing and treating angioedema including macular degeneration, macular edema, retinal edema, or varicose veins.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: January 21, 2020
    Assignee: Korea Institute of Oriental Medicine
    Inventors: Jin Sook Kim, Junghyun Kim, Chan-Sik Kim, Eunjin Shon, Yun Mi Lee, Young Sook Kim, Sojin Choi, Ik Soo Lee, Dong Ho Jung, Bo-Jeong Pyun, Seung-Hyun Jung
  • Patent number: 10537604
    Abstract: A method for enhancing at least one of alertness, attention, concentration and memory in a person in need thereof, comprising administering a composition to said person, said composition comprising: a) an effective amount of an extract of Cyperus esculentus peel, Cyperus esculentus rhizomes, or a combination thereof; b) an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; or c) a synergistic combination of (a) and (b).
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: January 21, 2020
    Assignee: NEKTIUM PHARMA, S.L.
    Inventors: Miguel Jimenez del Rio, Julia C. Wiebe, Laura Lopez-Rios, Tanausu Vega-Morales, Ruben Perez-Machin, Alvaro Sanchez-Rodriguez, Carlos Mateos, Nigel Peter Gericke
  • Patent number: 10537605
    Abstract: Provided is a plant extract composition and a pharmaceutical composition thereof for reducing body weight and body fat, wherein the plant extract composition comprises a green tea extract and a turmeric extract respectively 30 wt % to 75 wt % and 20 wt % to 55 wt % of a total weight of the composition. In diet-induced obesity models, either obesity is induced first or simultaneously with administration, the plant extract composition and a pharmaceutical composition thereof can reduce body weight and body fat more significantly than a single plant extract or commercially available weight loss drugs.
    Type: Grant
    Filed: August 28, 2015
    Date of Patent: January 21, 2020
    Assignee: CALIWAY BIOPHARMACEUTICALS CO., LTD.
    Inventor: Yu-Fang Ling
  • Patent number: 10537606
    Abstract: The present disclosure relates to a formulation for preventing and treating cancer which avoids the undesirable side effects observed when using the conventional therapies. The formulation in accordance with the present disclosure comprises a formulation having active constituents comprising a combination of extracts from Boswellia spp, Curcuma longa and Vitis vinifera.
    Type: Grant
    Filed: January 6, 2015
    Date of Patent: January 21, 2020
    Assignee: OMNI CURE LTD.
    Inventors: Jatin Thakkar, Gisli Örn Lárusson
  • Patent number: 10537607
    Abstract: Provided herein are novel compositions, specifically, caveolin modulators, and methods to treat and/or prevent autoimmune and/or inflammatory diseases/conditions using such compositions.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: January 21, 2020
    Assignee: E&B Technologies LLC
    Inventors: David Eveleth, William C. Sessa
  • Patent number: 10537608
    Abstract: Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier, and administering a therapeutic agent. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.
    Type: Grant
    Filed: August 14, 2017
    Date of Patent: January 21, 2020
    Assignee: ALLYSTA PHARMACEUTICALS, INC.
    Inventor: Henry Hsu
  • Patent number: 10537609
    Abstract: Pseudomonas aeruginosa flagellin protein recruits the mammalian host sialidase enzyme neuraminidase-1 (NEU1) to remove sialic acid residues from the extracellular domain of the mammalian cell-surface protein MUC1 (MUC1-ED), thereby exposing a cryptic binding site on the MUC1-ED protein backbone for flagellin binding. NEU1-driven MUC1-ED desialylation rapidly increases P. aeruginosa adhesion to the airway epithelium. MUC1-ED desialylation also increases MUC1-ED cleavage and shedding from the cell surface, where desialylated, shed MUC1-ED competitively blocks P. aeruginosa adhesion to cell-associated MUC1-ED. Presented herein are data showing that exogenously-administered, deglycosylated MUC1-ED peptides reduced adhesion of P. aeruginosa to airway epithelial cells. Also presented are data showing that administration of P. aeruginosa to mice in combination with deglycosylated MUC1-ED decreased P. aeruginosa recovered from the lungs at 48 hr and 72 hr post-infection.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: January 21, 2020
    Assignee: UNIVERSITY OF MARYLAND, BALTIMORE
    Inventors: Erik P. Lillehoj, Avelino C. Verceles, Simeon E. Goldblum
  • Patent number: 10537610
    Abstract: Methods for treating breast cancer, the methods can include administering to a subject an effective amount of a cell adhesion molecule Receptor (F11R peptide).
    Type: Grant
    Filed: October 24, 2018
    Date of Patent: January 21, 2020
    Inventors: Anna Babinska, Radoslaw Bednarek, Elizabeth Kornecki, Moro O. Salifu, Yigal H. Ehrlich, Maria Swiatkowska, Cristina C. Clement
  • Patent number: 10537611
    Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: January 21, 2020
    Assignee: Five Prime Therapeutics, Inc.
    Inventors: Thomas Harding, Servando Palencia, Li Long, Kevin Hestir
  • Patent number: 10537612
    Abstract: An object of the present invention is to provide a lyophilized formulation having improved storage stability of hepatic growth factor compared to conventional lyophilized formulations. The present invention provides a lyophilized formulation comprising (1) a hepatic growth factor, (2) trehalose and (3) one or more compounds selected from the group consisting of arginine, histidine, lysine, meglumine, glutamic acid, aspartic acid, proline, creatine, creatinine, tris(hydroxymethyl)aminomethane, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: January 21, 2020
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Ryo Ohori, Kanta Horie
  • Patent number: 10537613
    Abstract: The present invention provides a CXCL121 peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: January 21, 2020
    Assignee: The Medical College of Wisconsin, Inc.
    Inventors: Brian Volkman, Joshua Ziarek, Christopher Veldkamp, Francis Peterson
  • Patent number: 10537614
    Abstract: The present invention relates to pharmaceutical compositions for a combination therapy with a corticosteroid and exosomes. By means of the combination therapy diseases such as osteoarthritis, arthritis and/or degenerative spinal diseases can be treated.
    Type: Grant
    Filed: June 12, 2017
    Date of Patent: January 21, 2020
    Assignee: ORTHOGEN AG
    Inventors: Peter Wehling, Julio Reinecke
  • Patent number: 10537615
    Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
    Type: Grant
    Filed: March 14, 2018
    Date of Patent: January 21, 2020
    Assignee: Altor Bioscience, LLC
    Inventors: Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong